Biosecurity Organizations (Overview)
Overview
The biosecurity organizational landscape relevant to AI-era risks spans established institutions with decades of policy influence, EA-funded startups building novel technical infrastructure, and traditional international partnerships operating at billion-dollar scale. These organizations collectively address the growing convergence of AI capabilities and biological risks through approaches ranging from DNA synthesis screening to pathogen surveillance to vaccine development.
The funding landscape is heavily shaped by Coefficient Giving, which has directed over $90M to organizations in this set. Outside EA, CEPI operates at a fundamentally different scale ($760M+ raised, $3.5B five-year plan) but focuses primarily on natural pandemic threats rather than deliberate misuse.
Identity and Approach
| Organization | Founded | Approach | Threat Focus | Key Output |
|---|---|---|---|---|
| JHU CHS | 1998 | Detect, Governance | Both | Event 201 pandemic simulation; WHO Collaborating Centre |
| CEPI | 2017 | Defend | Natural | 8 authorized COVID vaccines; 100 Days Mission |
| NTI | bio | ≈2016 | Delay, Governance | Both | Spawned IBBIS; Global Health Security Index |
| SecureBio | 2022 | Delay, Detect, Defend | AI-enabled | Virology Capabilities Test (VCT); Nucleic Acid Observatory |
| SecureDNA | 2022 | Delay | Deliberate | Cryptographic DNA screening at 30bp (exceeds US requirements) |
| CLTR | ≈2021 | Governance | Both | UK MoD AI Strategy influence; Biological Security Strategy input |
| Blueprint Biosecurity | 2023 | Defend | Natural + deliberate | 266-page far-UVC Blueprint; EXHALE research grants |
| IBBIS | 2024 | Delay, Governance | Deliberate | Common Mechanism open-source screening tool |
| 1Day Sooner | 2020 | Defend, Governance | Natural | UK COVID challenge trial advocacy; air safety report |
| CSR | 2017 | Governance | Systemic | MiRCH climate-military tracker; systemic risk briefings |
| Red Queen Bio | 2025 | Defend | AI-enabled | None yet (launched Nov 2025) |
Approach uses SecureBio's Delay/Detect/Defend framework plus Governance. Threat Focus distinguishes natural pandemics, deliberate/engineered threats, and AI-enabled biological risks.
Funding and Assessment
| Organization | EA Funding | OP Funding | Non-EA Funding | Impact | Promise |
|---|---|---|---|---|---|
| JHU CHS | >$40M | >$40M | >$23M (CDC, Sloan, DoD) | A | B+ |
| CEPI | $0 | $0 | $760M+ (govts, Gates, Wellcome) | A | B |
| NTI | bio | >$29M | >$29M | Parent NTI: $250M (Turner) | A- | B+ |
| SecureBio | ≈$9.4M | ≈$9.4M | Minimal identified | B+ | A- |
| SecureDNA | Indirect (via SecureBio) | Indirect | Private philanthropy (US, EU, China) | B | B+ |
| CLTR | ≈$8M+ | ≈$5M | Private foundations | B | B+ |
| Blueprint Biosecurity | ≈$2M | ≈$1.85M | ≈$250K (Vanguard Charitable) | C+ | B+ |
| IBBIS | $3M (Founders Pledge) | $0 direct | Paris Peace Forum support | C+ | B |
| 1Day Sooner | ≈$7.8M | ≈$5.6M | ≈$5M (Schmidt, Packard, etc.) | C+ | B- |
| CSR | $0 | $0 | ≈$3.7M (MacArthur, Mertz Gilmore) | C | C |
| Red Queen Bio | $0 | $0 | $15M (OpenAI-led seed round) | D | B |
EA Funding includes Coefficient Giving, Founders Pledge, Survival and Flourishing Fund, EA Infrastructure Fund, and Emergent Ventures. Impact reflects demonstrated achievements to date. Promise reflects potential given positioning, approach, and resources. Both use A (highest) through F (lowest).
Rating Rationale
- A/A- impact: JHU CHS (25+ years of policy influence, Event 201, WHO Collaborating Centre), CEPI (8 authorized COVID vaccines, est. 2.7M deaths averted), NTI | bio (spawned IBBIS, GHS Index, Bio Funders Compact)
- B+/B impact: SecureBio (VCT adopted by major AI labs, NAO monitoring 31 sites), SecureDNA (deployed cryptographic screening exceeding US requirements), CLTR (documented UK policy wins on small budget)
- C+/C impact: Blueprint (impressive research output but young), IBBIS (Common Mechanism deployed but only 15% provider adoption), 1Day Sooner (UK challenge trial success, broad portfolio), CSR (traditional think tank, biosecurity not primary focus)
- D impact: Red Queen Bio (launched Nov 2025, no demonstrated output yet)
- A- promise: SecureBio (unique position at AI-bio intersection, VCT becoming industry standard)
- B+ promise: JHU CHS, NTI | bio, SecureDNA, CLTR, Blueprint (each has strong positioning with different risk profiles)
- B promise: CEPI (mature but structural tensions on equity), IBBIS (addresses critical gap), Red Queen Bio (novel thesis, OpenAI backing, but unproven)
Coefficient Giving Concentration
Coefficient Giving is the dominant funder in EA-aligned biosecurity. Six of the eleven organizations receive OP funding, and for several it constitutes the majority of their budget:
| Organization | OP Funding | % of Org's Total | Grant Period |
|---|---|---|---|
| JHU CHS | >$40M | ≈65% | 2017-2023 |
| NTI | bio | >$29M | Large majority | 2018-2023 |
| SecureBio | ≈$9.4M | ≈100% | 2022-2023 |
| 1Day Sooner | ≈$5.6M | ≈44% | Ongoing |
| CLTR | ≈$5M | ≈50% | 2024 |
| Blueprint Biosecurity | ≈$1.85M | ≈82% | 2023-2024 |
| Total identified | >$90M |
This concentration creates both strength (coordinated strategy) and risk (single point of funding failure). SecureBio derives nearly 100% of identified funding from Coefficient Giving.
Two organizations operate entirely outside the EA funding ecosystem:
- CEPI: $760M+ from governments and traditional philanthropy. Dwarfs all EA biosecurity funding combined.
- Red Queen Bio: $15M seed round led by OpenAI — the first major AI lab direct investment in biosecurity infrastructure.
Notable Patterns
Synthesis screening convergence: Three organizations work on DNA synthesis screening with complementary approaches — SecureDNA (cryptographic privacy-preserving tool), IBBIS (open-source Common Mechanism + international standards), and NTI | bio (governance advocacy). IBBIS was originally incubated within NTI | bio.
AI lab engagement: The biosecurity field is seeing growing direct engagement from AI labs. OpenAI led Red Queen Bio's $15M seed round. SecureBio's VCT is used by major AI labs for pre-release safety evaluations. JHU CHS has convened meetings with OpenAI, Anthropic, DeepMind, and others on AIxBio risks.
Age vs. demonstrated impact: The oldest organization (JHU CHS, 1998) has the clearest demonstrated impact, while the newest (Red Queen Bio, 2025) has the most novel thesis but no output yet. This expected pattern makes "promise" ratings more speculative for newer organizations.
Far-UVC convergence: Both Blueprint Biosecurity and 1Day Sooner work on far-UVC/indoor air quality from different angles — Blueprint through comprehensive research and deployment blueprints, 1Day Sooner through policy advocacy and cost-effectiveness analysis with Rethink Priorities.
Key Uncertainties
Key Questions
- ?How would an Coefficient Giving funding reduction affect the biosecurity landscape, given that multiple organizations derive 50-100% of funding from OP?
- ?Will AI lab direct investment in biosecurity (like OpenAI's Red Queen Bio investment) become a significant funding stream, or was this an isolated case?
- ?Can DNA synthesis screening achieve near-universal adoption before benchtop synthesizers make centralized screening obsolete?
- ?Is the current organizational landscape adequate for AI-enabled biological threats, or are there critical capability gaps that existing organizations don't address?
- ?How should the field balance natural pandemic preparedness (CEPI's focus) with deliberate misuse prevention (the EA biosecurity focus)?